×
About 12,193 results

ALLMedicine™ Diffuse Large B-cell Lymphoma Center

Research & Reviews  4,059 results

Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cel...
https://doi.org/10.1097/DAD.0000000000002053
The American Journal of Dermatopathology; Abbott J, Corean J et. al.

May 19th, 2022 - Histological transformation (HT) is an exceptionally uncommon and poorly understood event where a low-grade or indolent B-cell lymphoma transforms into a more aggressive entity, typically diffuse large B-cell lymphoma (DLBCL). The pathogenesis is ...

CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to...
https://doi.org/10.1111/cas.15402
Cancer Science; Dong L, Huang J et. al.

May 18th, 2022 - Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy with a high relapse rate of up to 40%. The prognosis of the disease remains improvement and requires a understanding of its molecular mechanism. We investigated the mecha...

THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B...
https://doi.org/10.1182/blood.2021014663
Blood Calabretta E, Hamadani M et. al.

May 18th, 2022 - Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirin...

Bone marrow and peripheral blood involvement of relapsed diffuse large B-cell lymphoma ...
https://doi.org/10.1111/ijlh.13860
International Journal of Laboratory Hematology; Chang SH

May 17th, 2022 - The author report an interesting case of relapsed diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) and peripheral blood (PB) involvement after prior cold agglutinin disease (CAD). A minority of patients with DLBCL present with CAD, and ...

CAR T-cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinic...
https://doi.org/10.1182/blood.2022016226
Blood Ali A, Goy A et. al.

May 14th, 2022 - Recently, significant progress has been made in identifying novel therapies, beyond conventional immunochemotherapy strategies, with efficacy in B-cell lymphomas. One such approach involves targeting the CD19 antigen on B-cells with autologous-der...

see more →

Guidelines  8 results

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Guidelines for the diagnosis and management of primary central nervous system diffuse l...
https://doi.org/10.1111/bjh.15661
British Journal of Haematology; Fox CP, Phillips EH et. al.

Nov 24th, 2018 - Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.|2018|Fox CP,Phillips EH,Smith J,Linton K,Gallop-Evans E,|diagnosis,therapy,diagnosis,therapy,

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lym...
https://doi.org/10.1016/j.ijrobp.2017.12.005
International Journal of Radiation Oncology, Biology, Phy... Ng AK, Yahalom J et. al.

Feb 8th, 2018 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will s...

Guidelines for diagnosis, prevention and management of central nervous system involveme...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286932
Haematologica Peñalver FJ, Sancho JM et. al.

Nov 16th, 2016 - Diffuse large B-cell lymphoma patients have a 5% overall risk of central nervous system events (relapse or progression), which account for high morbidity and frequently fatal outcomes,1 and shortened overall survival of <6 months.2 Early diagnosis...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  169 results

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03255018

May 13th, 2022 - Background: Gray-zone lymphomas (GZL) are rare, aggressive lymphomas that share clinical and biological features of diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma Standard upfront therapy for GZL is dose-intensive chemotherapy, though ...

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT00339963

May 13th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03888105

May 10th, 2022 - Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by indepen...

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
https://clinicaltrials.gov/ct2/show/NCT04404283

May 10th, 2022 - Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the t...

see more →

News  632 results

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

Lisocabtagene Maraleucel Approved in Europe for Select Relapsed/Refractory LBCL
https://www.onclive.com/view/lisocabtagene-maraleucel-approved-in-europe-for-select-relapsed-refractory-lbcl

Apr 22nd, 2022 - The European Commission has granted marketing authorization to the CD19-directed CAR T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi) for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary ...

CAR T-Cell Therapy Earns Indication for Lymphoma in First Relapse
https://www.medpagetoday.com/hematologyoncology/hematology/98024

Apr 4th, 2022 - The FDA approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) as initial treatment for relapsed/refractory large B-cell lymphoma (LBCL). The action moves CAR T-cell therapy to the earliest approved...

FISH Testing Guides Treatment of CLL: New Drugs on Horizon
https://www.onclive.com/view/fish-testing-guides-treatment-of-cll-new-drugs-on-horizon

Mar 15th, 2022 - Susan O'Brien, MD Fluorescence in situ hybridization (FISH) testing for genetic abnormalities is the key to appropriate treatment selection for patients with chronic lymphocytic leukemia (CLL), according to Susan M. O’Brien, MD, professor of Med...

see more →